The deal at a glance
$20M
Series A round
$175.6M
Pre money valuation
94%
Clinical sensitivity & specificity
$500M+
Projected revenue by 2032
The Round
Series A terms
Accredited investors ($200K in annual revenues or 300K together with spouse or $1M in assets) can join now under the following terms:
Round
Series A
Round size
$20M
Pre money valuation
$140M
Price per share*
$5.72
Stock class
Preferred A2
Minimum investment
$100,000
*Investments of $5M and above qualify for an additional discount.
Allocation of proceeds
Sales and commercial launch, 50%
R&D and platform, 15%
Clinical trials, 25%
Regulatory and operations, 10%
Traction and backing
Raised to date
$20.3M
$16.7M equity, $3.6M grants
Backed by
Hanaco, V Ventures, Menomadin
Plus angels including the founders of Wix, Timberland, Coffee Bean, Canyon Capital and Aleph
Market size
$42.4B
US cancer diagnostics and screening market, 2026
Roadmap
The path to $500M+ in revenue
A staged commercial ramp, direct to consumer first, then business to business. Pink marks the near term focus.
2027 · Launch
Direct to consumer
Online, physician ordered test goes live. 10K tests, $3.3M revenue, 44% gross margin.
2028 to 2029 · Scale
Grow DTC demand
Drive awareness and uptake. 150K tests, $29M revenue, gross margin up to 56%.
2030 to 2031 · Expand
Business to business
Employers, insurers, health systems, and strategic partnerships. 1M+ tests, $139M revenue.
2032 · Scale up
Category leader
2.5M+ tests and $500M+ revenue, with early Medicare and Medicaid adoption and multi cancer market share.
The Opportunity
A quick reminder of what sets this apart
A $42.4B market, one platform positioned to reshape it. SpotitEarly sits at the intersection of the AI revolution and multi cancer early detection. The thesis is simple.
1
A market failing on access
Only 14% of US cancers are found through recommended screening. Existing methods are invasive, costly, or inconvenient. The gap between who should be screened and who is, is enormous.
2
Validated and defensible
The LUCID Bio AI Hybrid platform is patent pending and clinically validated, with 94% sensitivity and specificity in early stage cancer. No predicate device exists, which supports a strong IP and regulatory position.
3
A pathway already open
As a Laboratory Developed Test run out of a CLIA certified laboratory, the test can be offered in the US today by physician order, while SpotitEarly continues to advance its FDA pathway.
Featured on:
Clinical Results
Proven in the Rainbow Study
A large scale, double blind clinical performance trial published in Scientific Reports (Nature).
Headline results: 93.9% sensitivity and 94.3% specificity across all stages, and higher early stage sensitivity than liquid biopsy.
"SpotitEarly is making early detection for multiple cancers faster, more accessible, and more affordable than anything I’ve seen in the field. This is a true breakthrough, and a chance to save lives at scale.״
Prof. David Sidransky
Professor of Oncology at Johns Hopkins School of Medicine.
97.0%
Lung sensitivity, early stage (0 to 2)
96.7%
Prostate sensitivity, early stage (0 to 2)
93.9%
Breast sensitivity, early stage (0 to 2)
86.4%
Colorectal sensitivity, early stage (0 to 2)
Early stage sensitivity across four cancer types: breast, lung, prostate, colorectal.
Let's talk
Leave your details
Share how you would like to continue the conversation and the team will be in touch directly.
select your investment amount
get up to 25% off your share price
Everyday investor
discount
Investment
Accredited Investor
Earns $200K+ a year or has $1M+ net worth
(
)
Im an
Accredited investor?
See your options
-
2%
3%
4%
share price
S 6.87
Total shares
2,256
Bonus
3%
Bonus
3%
Total w/Bonus
2,324
Youre $500 away from your next
4% bonus (+72 shares)
select your investment amount
get up to 25% off your share price
discount
Investment
$1K
$5K
$10K
$20K
2%
3%
4%
5%
6%
8%
10%
12.5%
15%
20%
25%
$50K
$100K
$200K
$250K
$500K
$1M
$5M
$10M+
Everyday investor
Accredited Investor
Earns $200K+ a year or has $1M+ net worth
(
)
Im an
Everyday investor?
See your options
share price
S 6.87
Total shares
2,256
Bonus
3%
Bonus
3%
Total w/Bonus
2,324
Youre $30,000 away from your next
5% bonus (+72 shares)
Join us on our journey to fight cancer and save lives
